Business Wire

VIKING-MALT

1.2.2024 09:01:30 CET | Business Wire | Press release

Share
Viking Malt partners up with Improvin’ to reduce supply chain emissions in barley

Viking Malt has set Science Based Targets, committing to a 42% reduction in greenhouse gas emissions from its own activities (Scope 1 & 2) by 2030. However, the majority of Viking Malt’s total emissions, 87%, are Scope 3 emissions from their suppliers, mainly occurring on-farm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201888552/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Viking Malt, a globally acknowledged producer of malt, is introducing a new sustainability performance platform, developed by the Swedish technology company Improvin’. Photo: Viking Malt.

Many of Viking Malt’s customers are large enough to have reduction targets covering even their Scope 3 emissions. To support their clients in achieving this goal, Viking Malt is committed to working with its stakeholders across the supply chain, identifying areas for emissions reductions and adjusting processes and practices.

With barley sourced from farmers across Finland, Sweden, Denmark, Poland and Lithuania, Viking Malt has been seeking ways to effectively measure and reduce these emissions.

Annika Wilhelmson, VP of Sustainability, Innovation & Marketing at Viking Malt Group: “Our farmers are central to our sustainability journey. With this new platform, we're empowering over 1200 farmers across Europe to actively engage in climate-smart and sustainable farming. This enables us to track and validate the impact of their sustainable practices effectively and fosters a collaborative approach to reducing emissions.”

The new platform provides Viking Malt with a detailed overview of the farms’ sustainability performance, setting a foundation for sustainable farming initiatives in which growers can adjust their practices based on feedback that builds on real-time data.

With the platform’s scalable data collection, farmer reporting becomes easy. “We want our farmers to be able to focus on sustainable and profitable agriculture, not extensive reporting,” Annika emphasizes.

The new platform equips Viking Malt with a verified ingredient footprint, biodiversity data and supply chain insights that they can share with their network of breweries, distilleries and food manufacturers. Viking Malt expects this transparency to drive positive change across the industry.

Annika concludes: “Our commitment to sustainable food and beverage production is shared by the industry. Success requires a collaborative approach throughout, and even beyond, our own value chain. We're excited to lead and inspire our partners and customers on this journey.”

Niklas Wallsargård, CEO of Improvin’ adds: “We're both proud and excited to work with Viking Malt, a family company showing deep commitment to drive sustainable impact through their products. Together, we can drive a meaningful change in this industry.”

About Viking Malt

Viking Malt is a globally acknowledged producer of malt for breweries, distilleries, and food manufacturers. With six malt houses in Sweden, Denmark, Finland, Lithuania, and Poland, Viking Malt offers a diverse range of malt varieties, catering to the unique needs of their customers. The company advocates for increased sustainability through malt by promoting regenerative farming practices, continuously improving energy and water efficiency in the malting process, reducing emissions, and leading innovation in new types of malts.

About Improvin’

Improvin’ is a Swedish technology company providing a sustainability performance platform for the agri-food industry. Food brands, processors and mills use the platform to quantify, verify and report emissions from their primary production and collaborate with their suppliers to reduce emissions and enhance biodiversity. Improvin's digital infrastructure enables agri-food businesses to incorporate sustainability into their existing sourcing processes while meeting regulatory standards for reporting with primary data.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201888552/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye